3/23
12:45 pm
insm
Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript [Seeking Alpha]
Low
Report
Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript [Seeking Alpha]
3/23
12:32 pm
insm
Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains [Yahoo! Finance]
Low
Report
Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains [Yahoo! Finance]
3/23
10:27 am
insm
Insmed shares rise on positive late-stage trial results for lung disease therapy [Yahoo! Finance]
Low
Report
Insmed shares rise on positive late-stage trial results for lung disease therapy [Yahoo! Finance]
3/23
09:49 am
insm
Insmed (INSM) had its price target lowered by Wells Fargo & Company from $208.00 to $175.00. They now have an "overweight" rating on the stock.
Low
Report
Insmed (INSM) had its price target lowered by Wells Fargo & Company from $208.00 to $175.00. They now have an "overweight" rating on the stock.
3/23
07:33 am
insm
S&P 500 Futures Rise in Premarket Trading; Insmed, Mobileye Global Lead [Barron's]
Low
Report
S&P 500 Futures Rise in Premarket Trading; Insmed, Mobileye Global Lead [Barron's]
3/23
07:09 am
insm
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease [Yahoo! Finance]
Low
Report
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease [Yahoo! Finance]
3/23
07:00 am
insm
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
Low
Report
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
3/16
10:58 am
insm
Insmed (INSM) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Low
Report
Insmed (INSM) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
3/10
11:02 am
insm
Insmed Incorporated (INSM) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Low
Report
Insmed Incorporated (INSM) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
3/5
07:00 am
insm
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3/3
08:35 am
insm
Is It Time To Reassess Insmed (INSM) After A 92% One Year Surge? [Yahoo! Finance]
Low
Report
Is It Time To Reassess Insmed (INSM) After A 92% One Year Surge? [Yahoo! Finance]
3/2
12:23 pm
insm
Insmed Incorporated (INSM) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
Low
Report
Insmed Incorporated (INSM) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
3/1
01:39 am
insm
Insmed Incorporated (INSM) Enters 2026 With Momentum [Yahoo! Finance]
Medium
Report
Insmed Incorporated (INSM) Enters 2026 With Momentum [Yahoo! Finance]
2/27
12:00 am
insm
Why Insmed Incorporated (INSM) is One of the Best Strong Buy Healthcare Stocks to Invest In [Yahoo! Finance]
Low
Report
Why Insmed Incorporated (INSM) is One of the Best Strong Buy Healthcare Stocks to Invest In [Yahoo! Finance]
2/25
08:23 am
insm
Melodia Therapeutics Announces U.S. Patent Grant Covering MLD-151 [Yahoo! Finance]
Medium
Report
Melodia Therapeutics Announces U.S. Patent Grant Covering MLD-151 [Yahoo! Finance]
2/24
08:54 am
insm
Insmed (NASDAQ:INSM) had its price target lowered by analysts at Mizuho from $211.00 to $204.00. They now have an "outperform" rating on the stock.
Low
Report
Insmed (NASDAQ:INSM) had its price target lowered by analysts at Mizuho from $211.00 to $204.00. They now have an "outperform" rating on the stock.
2/24
07:30 am
insm
Insmed Incorporated (INSM) Gained from Its Lead Product ARIKAYCE [Yahoo! Finance]
Low
Report
Insmed Incorporated (INSM) Gained from Its Lead Product ARIKAYCE [Yahoo! Finance]
2/23
08:04 am
insm
Insmed (NASDAQ:INSM) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $230.00 price target on the stock.
Low
Report
Insmed (NASDAQ:INSM) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $230.00 price target on the stock.
2/20
11:04 am
insm
Insmed Q4 Reinforces Confidence in Brinsupri Growth, RBC Says [Yahoo! Finance]
Low
Report
Insmed Q4 Reinforces Confidence in Brinsupri Growth, RBC Says [Yahoo! Finance]
2/20
10:57 am
insm
Insmed (NASDAQ:INSM) was given a new $166.00 price target on by analysts at Morgan Stanley.
Low
Report
Insmed (NASDAQ:INSM) was given a new $166.00 price target on by analysts at Morgan Stanley.
2/20
07:18 am
insm
Insmed (NASDAQ:INSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Low
Report
Insmed (NASDAQ:INSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
2/20
04:07 am
insm
Insmed (INSM) Poised for 2026 Upside With Potential $1.3B Arikayce Sales Boost, Roth/MKM Initiates Buy [Yahoo! Finance]
Low
Report
Insmed (INSM) Poised for 2026 Upside With Potential $1.3B Arikayce Sales Boost, Roth/MKM Initiates Buy [Yahoo! Finance]
2/19
03:08 pm
insm
Insmed (NASDAQ:INSM) was given a new $205.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Insmed (NASDAQ:INSM) was given a new $205.00 price target on by analysts at Stifel Nicolaus.
2/19
12:45 pm
insm
Insmed Incorporated Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Insmed Incorporated Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/19
11:43 am
insm
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
Low
Report
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say [Yahoo! Finance]